By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics said today that it has agreed to buy personalized diagnostics company RedPath Integrated Pathology in a deal that could be worth a total of $32 million.

Paris-based ExonHit plans to buy RedPath, a developer of DNA-based cancer tests, for $12.5 million upfront, another $10 million in stock, and for sales milestone payments that could total another $9.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.